| 107.39 -2.73 (-2.48%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 136.74  |
1-year : | 144.29 |
| Resists | First : | 117.08 |
Second : | 123.54 |
| Pivot price | 114.34 |
|||
| Supports | First : | 106.62 |
Second : | 88.71 |
| MAs | MA(5) : | 110.36 |
MA(20) : | 114.81 |
| MA(100) : | 104.78  |
MA(250) : | 87.44 |
|
| MACD | MACD : | -1.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 15.9 |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 130.05 | Low : | 55.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KYMR ] has closed above bottom band by 3.2%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 111.36 - 112.06 | 112.06 - 112.55 |
| Low: | 105.01 - 105.86 | 105.86 - 106.46 |
| Close: | 106.27 - 107.52 | 107.52 - 108.4 |
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Fri, 02 Oct 2026
B.Riley keeps Buy rating for Kymera Therapeutics stock - ad-hoc-news.de
Thu, 01 Oct 2026
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada
Thu, 01 Oct 2026
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - Stock Titan
Thu, 01 Oct 2026
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - Stock Titan
Wed, 30 Sep 2026
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm - morningstar.com
Mon, 28 Sep 2026
JPMorgan Flags Kymera Therapeutics (KYMR) for Positive Catalyst Ahead of Phase 2b Trial Results - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 117.1 (%) |
| Shares Short | 10,380 (K) |
| Shares Short P.Month | 9,900 (K) |
| EPS | -3.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.22 |
| Profit Margin | -285.4 % |
| Operating Margin | -116.4 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | -24.2 % |
| Qtrly Rev. Growth | 466.3 % |
| Gross Profit (p.s.) | -3.29 |
| Sales Per Share | 1.27 |
| EBITDA (p.s.) | -4.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -237 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -33.05 |
| PEG Ratio | 0 |
| Price to Book value | 5.89 |
| Price to Sales | 84.13 |
| Price to Cash Flow | -37.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|